Alcohol use disorder and the liver

Ryan Buchanan & Julia M. A. Sinclair
Department of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK

ABSTRACT

Alcohol use disorders (AUD) cause a range of physical harms, but the major cause of alcohol-related mortality is alcohol-related liver disease (ALD), in some countries accounting for almost 90% of alcohol-related deaths. The risk of ALD has an exponential relationship with increasing alcohol consumption, but is also associated with genetic factors, other lifestyle factors and social deprivation. ALD includes a spectrum of progressive pathology, from liver steatosis to fibrosis and liver cirrhosis. There are no specific treatments for liver cirrhosis, but abstinence from alcohol is key to limit progression of the disease. Over time, cirrhosis can progress (often silently) to decompensated cirrhosis and hepatocellular carcinoma (HCC). Liver transplantation may be suitable for patients with decompensated liver cirrhosis and may also be used as a curative intervention for HCC, but only for a few selected patients, and complete abstinence is a prerequisite. Patients with AUD are also at risk of developing alcoholic hepatitis, which has a high mortality and limited evidence for effective therapies. There is a strong evidence base for the effectiveness of psychosocial and pharmacological interventions for AUD, but very few of these have been trialled in patients with comorbid ALD. Integrated specialist alcohol and hepatology collaborations are required to develop interventions and pathways for patients with ALD and ongoing AUD.

Keywords Alcohol-related liver disease, alcohol use disorder, cirrhosis, hepatitis, hepatocellular carcinoma, relapse prevention.

Correspondence to: Julia Sinclair, Department of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton Mailpoint 806, Level D, Southampton General Hospital, Southampton SO16 6YD, UK. E-mail: julia.sinclair@soton.ac.uk
Submitted 28 April 2020; initial review completed 19 June 2020; final version accepted 17 July 2020

INTRODUCTION

The World Health Organization estimate that harmful alcohol consumption is the seventh leading cause of global death and disability [1]. Alcohol causes a wide spectrum of pathology, but alcohol-related liver disease (ALD) causes a significant proportion of the attributable morbidity and mortality [1]. This proportion varies geographically and is generally highest in middle-aged males. In some areas, such as the United Kingdom, almost 90% of alcohol-related deaths are caused by ALD (Fig. 1) [1,2].

Until the 1970s the association between alcohol and liver cirrhosis had been noted, but doubt about a causal relationship persisted. Uncertainty gained traction because not all people with alcohol use disorder (AUD) developed cirrhosis, but it was often observed when malnutrition was also present. This led to debate concerning whether it was malnutrition rather than alcohol that was the primary risk factor for liver cirrhosis. However, a team working in New York settled the argument. Leiber et al. fed ethanol to 15 baboons as part of an otherwise balanced nutritious diet. The team observed the whole spectrum of alcohol-related liver disease (ALD) and glimpsed the underlying pathogenic pathway [3].

Since the 1970s, alcohol has become more available and the incidence of ALD has increased. This review summarizes the latest epidemiology of ALD and gives an overview of the spectrum of attributable liver pathology. It also synthesizes the evidence for best practice in clinical hepatology and addiction psychiatry to understand and manage this complex comorbid condition.

Epidemiology of alcohol-related liver disease

In 2017 liver disease caused more than 1.32 million deaths worldwide. In Europe, North and South America and Central Asia the most common cause of liver cirrhosis is ALD [4]. Countries in the European region consume some of the highest quantities of alcohol [5], with more than 2 million years of life lost to liver disease in people under the age of 50 years, with 60–80% of these attributed to alcohol [6]. In some European countries, notably Finland and the United Kingdom, there has been an increase in ALD-related deaths in recent decades which has been
associated with a reduction in the relative price of alcohol and a steep rise in consumption [2,6].

An overall increase in alcohol consumption has been noted world-wide [5,7], including in the United States [8], where there has been a significant rise in the prevalence of harmful consumption of alcohol [9], and a corresponding 65% increase in annual liver cirrhosis mortality since 2009. Notably, this increased mortality can be attributed almost entirely to ALD in young people [8].

At an individual level the probability of developing ALD has a close and exponential relationship with levels of alcohol consumption [10–12]. However, risks of ALD are increased with only modestly elevated levels of consumption [12]. ALD has also been associated with a number of genetic polymorphisms [13], and is more likely in people with comorbid obesity or chronic viral hepatitis [14,15]. Social deprivation is also a significant risk factor, with individuals in the two lowest quintiles of the Index of Multiple Deprivation, and particularly those who are homeless are at greatest risk of liver morbidity and mortality [16–19]. This is thought to be a consequence of the increased affordability of alcohol [6] and the high prevalence of multiple-risk comorbidities in these populations, including hepatitis C, smoking, obesity and a lack of exercise [16]. The combination of alcohol with a range of other factors which cause harm to health may account for the so-called ‘alcohol harm paradox’, where deprived individuals drinking the same quantities of alcohol as more affluent individuals are disproportionately affected with ALD [16].

THE SPECTRUM OF ALCOHOL-RELATED LIVER DISEASE

Excessive consumption of alcohol leads to a spectrum of liver disease, including liver steatosis, fibrosis, compensated cirrhosis (CC), decompensated cirrhosis (DC), hepatocellular carcinoma (HCC) and alcoholic hepatitis (AH) (see Fig. 2). A ‘fatty liver’ or steatosis is an extremely common finding in people who drink alcohol, and the accumulation of fat in the liver can occur after just a few days of drinking alcohol. The rate of progression of liver disease varies in different subpopulations, but is increased at all stages (steatosis to fibrosis through to DC and HCC) by the consumption of alcohol. Conversely, the rate of progression is reduced by abstinence [20]. AH is a distinct acute disease of the liver that usually occurs in people with AUD who have recently consumed large quantities of alcohol. It typically, but not exclusively, occurs in people with underlying liver cirrhosis (see Fig. 2) [21].

OVERVIEW OF HEPATIC METABOLISM OF ALCOHOL

Hepatocytes make up 70% of the liver mass and play the central role in alcohol metabolism. Within each cell there are three enzymic pathways for the metabolism of alcohol. The major pathway occurs in the cytoplasm of the hepatocytes. In this pathway ingested alcohol is oxidized by alcohol dehydrogenase to acetaldehyde. In a second pathway—the major inducible pathway—alcohol is oxidized to acetaldehyde in the smooth endoplasmic reticulum by the cytochrome p450 2E1 enzyme. In the third, more minor inducible pathway, alcohol is metabolized to acetaldehyde via a catalase enzyme. The acetaldehyde produced by all three pathways is toxic to the cell, so it is rapidly transported to the mitochondria where it is converted to acetate via an acetaldehyde dehydrogenase enzyme. The acetate then passes into the circulation to play a role in metabolism elsewhere.

HOW DOES ALCOHOL DAMAGE THE LIVER?

The mechanisms by which alcohol directly harms the liver sufficiently to cause chronic liver disease are complex. Excessive alcohol consumption increases the
production of enzymes necessary for its metabolism. This leads to increased levels of acetaldehyde and harmful pro-oxidants, which are directly cytotoxic to hepatocytes. As a natural response to tissue injury, fibrogenesis occurs to isolate and limit damage to a specific area of tissue. Fibrogenesis occurs because the liver injury activates hepatic stellate cells, which form extracellular matrix proteins and release inflammatory proteins that lead to a cycle of further activation, protein deposition and fibrogenesis. Cirrhosis is an advanced form of fibrosis where the normal liver micro- and macro-structure has been lost and is characterized by the development of regenerative nodules divided by fibrous septa. Liver cirrhosis is considered to be a pre-malignant condition. The processes leading to liver cirrhosis including tissue injury and repair, alongside directly mutagenic properties of the acetaldehyde and harmful pro-oxidants, create an environment prone to develop HCC.

The underlying causes of AH and the intense inflammatory infiltration of the liver that characterizes the condition are not completely understood. It is probable that a complex interplay of factors is involved. There is evidence that alcohol increases gut permeability, which leads to high levels of bacterial toxins (e.g. lipopolysaccharide endotoxin) passing from the gut into the circulation. In AH it is postulated that these activate inflammatory responses within the liver. Additionally, alcohol directly activates innate liver immune cells (called Kupffer cells) and sensitizes hepatocytes to some of the inflammatory proteins they produce leading to cell death. Hepatocyte death itself activates the inflammatory cascade, leading to further cell death, and in this way the pathogenesis of AH is sustained.

Figure 2. An overview of the spectrum of alcohol-related liver disease. Images courtesy of Dr M. Isabel Fiel (Fig. 1 from Crabb et al [36], reproduced with permission from John Wiley and Sons) [Colour figure can be viewed at wileyonlinelibrary.com]
LIVER FIBROSIS AND CIRRHOSIS

Clinical manifestations

Opportunities to screen for liver disease in patients with harmful alcohol consumption are often missed, and many patients only present to health services once symptoms relating to DC have occurred [22,23]. As indicated in Fig. 2, cirrhosis can progress from CC to DC at a rate of 5–7% per year [24]. As well as alcohol consumption, a range of factors, including infection, medications such as benzodiazepines, surgical operations such as heart valve replacements and gastrointestinal bleeding can trigger progression to DC. DC is characterized by the development of ascites (free fluid within the abdominal cavity), abnormal clotting, jaundice (yellow discoloration of the skin and sclera) and encephalopathy (resulting in confusion, drowsiness and coma).

Assessment

As alcohol-related liver fibrosis and CC develops silently over many years, the challenge is to make an early initial diagnosis. Accordingly, numerous targeted screening approaches have been developed in people who drink alcohol at high levels to try to identify disease at an earlier stage. According to European guidelines, targeted screening is appropriate in men drinking >30 g/day and women drinking >20 g/day of ethanol, but should also be considered in those presenting with other physical manifestations of AUD, such as cardiomyopathy and peripheral neuropathy [25].

Standard liver function tests including raised blood levels of the liver enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase are poor markers of ALD, and should only be considered in conjunction with a specific test for liver fibrogenesis [26]. A range of biochemical fibrosis markers are recommended for this assessment, including the enhanced liver fibrosis (ELF) test, fibrosis 4 (Fib4) test and FibroTest [25]. However, in the United Kingdom the current clinical guidelines on the management of cirrhosis recommend that patients with AUD be referred directly for transient elastography (TE) [27]. In TE a shear wave is transmitted through the liver and this gives a measure of liver stiffness in kilopascals (kpa). Liver stiffness correlates with the degree of liver fibrosis, and TE is therefore a useful non-invasive assessment for liver cirrhosis and advanced fibrosis [28]. In cases of diagnostic uncertainty, or to more accurately stage the degree of liver fibrosis, a liver biopsy is still appropriate in some cases. However, the additional diagnostic and prognostic information from a liver biopsy needs to be weighed against potential serious complications which occur following <2% of procedures [25,27]. Patients with DC usually present to health-care services with acute illness, and the diagnosis is apparent from clinical examination of the patient for hepatic encephalopathy, ascites and jaundice.

Treatment

There are no licensed pharmacological treatments to reverse ALD. Management is therefore focused upon monitoring for complications of cirrhosis, abstinence and other life-style modifications, such as weight loss and dietary modification—there is observational evidence that coffee reduces progression to cirrhosis [29]. For a small minority of patients with end-stage disease, liver transplantation (LT) may be required.

Patients with established liver cirrhosis should be monitored with ultrasonography for the development of HCC and with regular blood tests to assess their degree of liver function, including the ability to synthesize proteins that are essential for the normal functioning of the body. Consideration should also be given to a screening endoscopic examination for oesophageal varices (swollen veins in the oesophagus, due to congestion of the portal vein), which are at risk of rupture.

Abstinence from alcohol is key to preventing disease progression in patients with liver fibrosis and CC [30]. Indeed, even at an advanced stage, inflammation and fibrosis remain reversible on cessation of alcohol, and liver steatosis is considered to be fully reversible with appropriate life-style modifications [20]. Since the 1960s it has been observed that abstinence from alcohol is also key for preventing death in patients with decompensated ALD [31]. This is supported by recent prospective [32] and retrospective cohort studies [33].

All interventions for alcohol use disorders are underpinned by a psychosocial framework [34]. Although the evidence base for psychosocial treatment in patients in ALD is limited [30], a systematic review of treatment trials in ALD found that integrating specialist AUD treatment within hepatology services resulted in higher abstinence rates than referral to a separate treatment service [35]. Recent international ALD treatment guidance now recommends that to engage patients in harm reduction, or ideally achieve abstinence, appropriate psychosocial support services should be available within hepatology centres as part of an integrated multidisciplinary team [25,36].

Pharmacological treatment in patients with moderate to severe alcohol dependence may also be required for medically assisted alcohol withdrawal, or relapse prevention, especially given the many years of untreated AUD prior to presentation, and the need for long-term sustained abstinence. In terms of alcohol withdrawal, standard practice is variable but there is good evidence for the efficacy of benzodiazepines and carbamazepine for medically assisted withdrawal from alcohol, and preventing further
complications such as delirium and seizures [34]. For patients with decompensated liver cirrhosis, and impaired synthetic function, carbamazepine is not recommended and doses of benzodiazepine medication should be reduced, with frequent objective monitoring of symptoms [37]. In clinical practice, oxazepam or lorazepam, which have reduced hepatic metabolism are sometimes used [37]. Given the poor nutritional status of many patients with ALD, a high index of suspicion needs to be maintained for the development of Wernicke–Korsakoff syndrome and all patients in alcohol withdrawal should be treated with parenteral thiamine (usually in combination with other B vitamins) for 3–5 days until no symptoms (confusion, ataxia, ophthalmoplegia) remain or treatment continued until no further improvement in symptoms found [34].

Relapse prevention medication may also be considered (Table 1). Acamprosate, naltrexone, nalmefene and disulfiram are all approved in one or more region for the treatment of alcohol dependence [38]. Baclofen has been recently approved for AUD treatment in France only for patients who have not responded to other treatments [39].

Disulfiram inhibits the enzyme acetaldehyde dehydrogenase, causing accumulation of acetaldehyde following alcohol consumption, which can have potentially severe adverse effects and so should be used with caution, and only after a thorough assessment in patients with ALD [34]. There are also concerns about potential hepatotoxic effects of naltrexone [36] with five to 10-fold increases in naltrexone plasma concentrations reported in patients with cirrhosis [38,40]. However, data suggest that high doses (up to 300 mg daily), concurrent use of non-steroidal analgesics and obesity may account for the raised transaminases seen in early studies, and Phase 2 studies showed no evidence of toxicity at doses of 800 mg daily for 1 week. Nalmefene, another opioid system modulator, structurally similar to naltrexone, is extensively metabolized by the liver, largely by glucuronidation, and has not been identified to have a risk of hepatotoxicity, although one small study of patients with liver disease showed significantly reduced clearance of nalmefene inversely proportional to the level of hepatic pathology. Its efficacy has not been specifically investigated in patients with ALD [38].

Acamprosate is derived from homotaurine, a non-specific gamma aminobutyric acid (GABA) agonist and calcium. It is not metabolized by the liver and has no impact on drugs subject to hepatic metabolism or which have an impact upon the CP450 system. It is excreted via the kidneys, although there are no trials specifically assessing its effects in patients with ALD. Acamprosate should be considered as a treatment option in this patient group [38]. Only baclofen, a GABA-B receptor agonist, has been assessed in patients with established cirrhosis. In a single randomized controlled trial (RCT), patients who received baclofen were twice as likely to report abstinence than patients receiving placebo and no hepatotoxic effects were recorded [41]. Importantly, this study demonstrated the safety of baclofen in patients with DC. Conversely, a later RCT showed no benefit from baclofen compared to placebo. However, this trial was conducted in an exclusively male, relatively elderly cohort with hepatitis C and the studies used different outcomes measures, so direct comparison is difficult [42]. In recognition of this uncertainty, but mindful that it is the only relapse prevention medication to be trialled in patients with cirrhosis, an international consensus statement published in 2018

- **Table 1** Relapse prevention medications in patients with AUD and ALD (adapted from AASLD [36]).

| Medication       | Metabolism/excretion | Mechanism of action | Evidence in ALD                                      | Recommended for AUD in ALD |
|------------------|----------------------|---------------------|------------------------------------------------------|-----------------------------|
| Baclofen         | Limited hepatic/     | GABA-B receptor     | 1 RCT showed benefit. 1 RCT showed no benefit, no harm | Can be considered [36,43]   |
|                  | mostly renal         | agonist             |                                                      |                             |
| Acamprosate      | None/renal           | NMDA receptor       | Not studied in ALD                                    | Can be considered [36]      |
|                  |                      | antagonist          |                                                      |                             |
| Naltrexone       | Hepatic/renal        | Opioid receptor     | Not studied in ALD                                    | Not recommended as first line [25,36] |
|                  |                      | antagonist          |                                                      |                             |
| Gabapentin       | None/renal           | GABA agonist        | Not studied in ALD                                    | Not recommended [25]        |
| Disulfiram       | Hepatic/renal,       | Inhibits aldehyde   | Case reports of hepatotoxicity Otherwise              | Avoid in severe ALD [25]    |
|                  | faeces, lung         | dehydrogenase       | not studied                                          |                             |
| Nalmefene        | Hepatic/renal        | Opioid receptor     | Not studied in ALD                                    | Consider in early stage ALD [25] |
| Topiramate       | Limited/renal        | Glutamate antagonist| Not studied in ALD                                    | Not recommended             |
|                  |                      | GABA agonist        |                                                      |                             |

RCT = randomized controlled trial; GABA = gamma aminobutyric acid; ALD = alcohol-related liver disease; AUD = alcohol use disorder; NMDA = N-methyl-D-aspartate.
recommended consideration of baclofen to treat AUD in patients with ‘advanced liver disease’ (see Table 1), and this has been supported by recent US guidance [36,43].

Liver transplantation

Abstinent patients with end-stage ALD or those with a range of extrahepatic manifestations can be considered for LT. ALD is increasingly an indication for LT in the United States [44] and Europe [45]. Since the late 1980s ALD has been considered an appropriate indication for LT, and although early survival rates were poor [46], 5-year post-transplant survival in patients with ALD is now comparable to patients transplanted for other indications and the 1-year post-transplant survival is greater than 80% [44]. However, patients with ALD are at risk from multisystem effects of alcohol including, cardiomyopathy, pancreatitis, dementia and malnutrition, and therefore pre-operative assessment needs to be rigorous [47]. Malnutrition is particularly common in patients with ALD [48] and is associated with worse outcomes [49].

Abstinence from alcohol is a prerequisite before a patient is considered for LT, and in many countries a strict 6-month period of abstinence is enforced; however, there is a lack of data supporting such a stringent approach and it is not endorsed by international guidelines. Nevertheless, a careful assessment of risk of relapse is essential. This should involve a multidisciplinary team and include careful exploration of risk factors for relapse, such as a family history of AUD, previous unsuccessful attempts at abstinence and poor social support networks [50,51].

Prognosis

Patients with CC have a 1-year survival of more than 90% [24]. The likelihood of complications and death in patients with DC correlates closely with scoring systems such as the Child–Turcott–Pugh score or the model for end-stage liver disease score [36]. The Child–Turcott–Pugh score places patients into three classes on the basis of the presence or absence of encephalopathy, jaundice, ascites or coagulopathy [52]. In a systematic review of more than 118 cohort studies, those with the most severe decompensated disease (class C) had a 1-year survival of less than 50% [24].

HEPATOCELLULAR CARCINOMA

Clinical manifestations

ALD is the most common cause of HCC in Europe and North America and accounts for 30% of cases world-wide [53]. For an individual with CC the annual probability of developing HCC is 2.9–5.6% per year, but the incidence is higher in individuals with DC (Fig. 2) [54].

In patients with known ALD, unexplained progression from CC to DC should lead to investigation for a possible HCC. Otherwise, tumour-specific symptoms, including right upper quadrant fullness, weight loss, anorexia or early satiety, are often vague and easily dismissed. Consequently, HCC is often identified during routine surveillance imaging in patients with ALD, or as an incidental finding in patients who have received imaging of their liver for an unrelated indication.

Despite international guidance advocating 6-monthly ultrasound imaging of the liver for patients with ALD, a significant proportion of cases present in patients who have not been effectively engaged with surveillance imaging programmes [54]. Accordingly, patients with ALD present with more advanced cancer and have worse outcomes than patients with HCC due to another underlying cause [55].

Assessment

In patients with established cirrhosis, computerized tomography (CT) or magnetic resonance imaging (MRI) imaging may be sufficient to establish the diagnosis if pathognomonic features are present. In patients without established cirrhosis or in cases where there is diagnostic uncertainty a biopsy for histology may be necessary, although interval imaging to assess changes in lesion size or character over a short time-period may sometimes be appropriate [56]. The investigation of liver lesions should always be directed by a cancer multidisciplinary service [56].

Treatment

The treatment of HCC in patients with ALD is complex and evolving. In the first instance it is important to establish whether the goal of therapy is palliative or curative. To determine which approach should be taken, a number of patient and tumour-related factors need to be considered. These include whether the patient has CC or DC; whether they would be considered a candidate for LT (i.e. are abstinent from alcohol); and tumour size, number and location within the liver.

Where potentially curative approaches are considered appropriate these may include radio-frequency ablation of the tumour, resection of the tumour or LT. Potential palliative approaches include trans-arterial chemo-embolization, systemic chemotherapy or best supportive care [56].

Prognosis

Prognosis of HCC varies depending on the treatment modality that can be offered. Patients with a small single tumour that is resected have a 5-year survival of 80–90%. In patients who successfully undergo LT, median 5-year survival is as high as 70%; however, where curative
therapy cannot be offered, 5-year survival is considerably lower, with those in a terminal stage of disease surviving just a few months [56].

**ALCOHOLIC HEPATITIS (AH)**

AH was first clinically defined in 1961 by clinicians working at the Royal Free Hospital in London [57]. It is a distinct clinical syndrome from DC and can occur in patients without established liver cirrhosis [21]. Patients typically present to medical services with jaundice following a recent escalation in alcohol consumption. Serum biochemistry tests show an elevated bilirubin but usually only a modest elevation in ALT. The liver is often enlarged and tender and the patient may complain of nausea, fevers and sometimes vomiting. Histology shows a characteristic inflammatory cell infiltrate alongside other distinctive features.

**Assessment**

History, examination and blood tests are an important part of the initial assessment to establish the level and duration of alcohol consumption and the clinical and biochemical features of AH. Liver biopsy is not an essential part of the diagnostic pathway but should be undertaken if there is diagnostic uncertainty. Imaging of the liver, usually via ultrasonography, is important to exclude other causes of jaundice and in the presence of fever clinicians should actively exclude infection.

**Treatment**

To achieve a positive outcome, it is essential that patients diagnosed with AH become completely abstinent. Most cases will be managed in hospital, where they can be monitored for complications and, in severe cases, consideration given to the provision of specific interventions.

In severe cases, corticosteroids are marginally beneficial for short-term survival but convey risks of infection and variceal bleeding, so should only be continued in patients who show a positive initial response [58]. A single trial showed a significant reduction in 1-month mortality by adding a 5-day infusion of N-acetylcysteine to prednisolone, although the reduction in mortality was non-significant in the longer term [59]. Oral or nasogastric tube feeding is also important. Poor nutrition is associated with adverse outcomes in AH [60], and nasogastric feeding has been shown to be comparable to corticosteroid therapy in a single randomized control trial [61], although a later study which combined nasogastric feeding and corticosteroid therapy was not found to be superior to corticosteroid therapy alone [60].

**Prognosis**

Even with treatment, severe alcoholic hepatitis has a high mortality. In a large UK-based four-arm RCT 28-day mortality rate ranged from 14 - 18%, and 58% of the cohort had died at 12 months [58]. A Spanish study of 142 patients with biopsy-proven AH has shown that abstinence from alcohol was the only factor significantly associated with long-term survival [62].

**New developments in treatment of AH**

In the absence of any treatment for AH that significantly improves long-term outcomes, trials focusing on hepatic (but not alcohol) treatment are ongoing [63]. LT is now being used in some countries as a therapeutic strategy for selected patients with AH. In 2011 a highly selected case series in France assessed outcomes for patients with AH receiving a liver transplant [64]. The study showed a significant survival benefit compared to matched controls in selected patients with severe alcoholic hepatitis and comparable survival outcomes to patients receiving LTs for other indications. Additionally, subsequent studies have shown that patients receiving a transplant for AH were no more likely to return to drinking than those receiving a transplant after a period of abstinence from alcohol [60]. However, although transplantation for AH now occurs in the United States and parts of Europe it has not become practice in the United Kingdom [65]. Indeed, a recent UK trial investigating the utility of LT in patients with AH failed to recruit any participants [65].

**CONCLUSION**

Despite overwhelming evidence of the high levels of morbidity and mortality due to liver disease in patients with AUD, and alcohol-related deaths in patients with liver disease, research and clinical practice aimed at developing a robust evidence base to improve outcomes in this comorbid group remains in its infancy. The paucity of evidence for integrated alcohol treatment in ALD is particularly surprising, given that abstinence improves outcomes at all stages of liver disease, and the evidence base for psychosocial and pharmacological treatment for patients with AUD is well established.

The re-purposing of the drug baclofen has shown some promise in developing collaborations to explore treatments in this comorbid group, but greater integration of both psychosocial and pharmacological treatment pathways across hepatology and addictions is needed before real progress will be made.

**Declaration of interests**

None.
References

1. GBD 2016 Alcohol Collaborators, Griswold MG, Fullman N, Hawley C, Arian N, Zimsen S R. M., Tyneson H. D., et al. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet 2018; 392: 1015–35.

2. Office for National Statistics (ONS). Number of deaths caused by alcoholic liver disease and other causes associated with the misuse of alcohol, deaths registered in England and Wales, 2016. Newport, UK: ONS. 2017.

3. Lieber C. S., DeCarli L., Rubin E. Sequential production of fatty liver, hepatitis, and cirrhosis in sub-human primates fed ethanol with adequate diets. Proc Natl Acad Sci USA 1975; 72: 437–41.

4. Global Burden of Disease Study (GBD) 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020; 5: 245–66.

5. Global status report on alcohol and health [internet], 2018 [cited 2020 Jul 6]. Available at: https://apps.who.int/iris/bitstream/handle/10665/274603/9789241563639-eng.pdf.

6. Sheron N. Alcohol and liver disease in Europe—simple measures have the potential to prevent tens of thousands of premature deaths. J Hepatol 2016; 64: 957–67.

7. Hydes T., Gilmore W., Sheron N., Gilmore I. Treating alcohol-related liver disease from a public health perspective. J Hepatol 2019; 70: 223–36.

8. Tanner E. B., Parikh N. D. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: observational study. BMJ 2018; 362: k2817.

9. Grant B. E., Chou S. P., Saha T. D., Pickering R. P., Kerridge B. T., Ruan W. J., et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States. 2001–2002 to 2012–2013. JAMA Psychiatry 2017; 74: 911–23.

10. Simpson R. E., Hermorn C., Liu B., Green J., Reeves G. K., Beral V., et al. Alcohol drinking patterns and liver cirrhosis risk: analysis of the prospective UK million women study. Lancet Public Health 2019; 4: e41–e48.

11. Bellentani S., Saccocio G., Costa G., Tiribelli C., Manenti F., Soda M., et al. Drinking habits as cofactors of risk for alcohol induced liver damage. Gut 1997; 41: 845–50.

12. Roerecke M., Vafaei A., Hasan O. S. M., Chrysosta B. R., Cruz M., Lee R., et al. Alcohol consumption and risk of liver cirrhosis. Am J Gastroenterol 2019; 114: 1574–86.

13. Meroni M., Longo M., Rametta R., Dongiovanni P. Genetic and epigenetic modifiers of alcoholic liver disease. Int J Mol Sci 2018; 19: 3857.

14. Hart C. L., Morrison D. S., Batty G. D., Mitchell R. J., Smith G. D. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ 2010; 340: c1240.

15. Hutchinson S. J., Bird S. M., Goldberg D. J. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol 2005 Nov; 3: 1150–9.

16. Bellis M. A., Hughes K., Nicholls J., Sheron N., Gilmore L., Jones L. The alcohol harm paradox: using a national survey to explore how alcohol may disproportionately impact health in deprived individuals. BMC Public Health 2016; 16: 111.

17. Aldridge R. W., Menezes D., Lewer D., Cornes M., Evans H., Blackburn R. M., et al. Causes of death among homeless people: a population-based cross-sectional study of linked hospitalisation and mortality data in England. Welcome Open Res 2019; 4: 49.

18. Siegler V., Al-Hamad A., Johnson B., Wells C., Sheron N. Social inequalities in alcohol-related adult mortality by National Statistics Socio-economic Classification, England and Wales, 2001–03. Health Stat Q 2011; 50: 4–39.

19. Erskine S., Maheswaran R., Pearson T., Gleeson D. Socioeconomic deprivation, urban-rural location and alcohol-related mortality in England and Wales. BMC Public Health 2010; 10: 99.

20. Teli M. R., Day C. P., Burt A. D., Bennett M. K., James O. F. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346: 987–90.

21. Philips C. A., Augustin P., Yerol P. K., Rajesh S., Mahadevan P. Severe alcoholic hepatitis: current perspectives. Hepatol Med 2019; 11: 97–108.

22. Verrill C., Smith S., Sheron N. Are the opportunities to prevent alcohol-related liver deaths in the UK in primary or secondary care? A retrospective clinical review and prospective interview study. Subst Abuse Prev Treat Policy 2006; 1: 16.

23. Jepsen P., Ott P., Andersen P. K., Sørensen H. T., Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010; 51: 1675–82.

24. D’Amico G., García-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217–31.

25. European Association for the Study of the Liver (EASL). Management of Alcohol-Related Liver Disease. Geneva, Switzerland: EASL 2018.

26. Ahmed Z., Ahmed U., Walayat S., Ren J., Martin D. K., Moode H., et al. Liver function tests in identifying patients with liver disease. Clin Exp Gastroenterol 2018; 11: 301–7.

27. National Institute for Health and Care Excellence (NICE). Overview|Cirrhosis in over 16s: assessment and management |Guidance [NICE |internet]. NICE: 2016 [cited 2019 Jul 29]. Available at: https://www.nice.org.uk/guidance/ng50.

28. Nuhon P., Kettaneh A., Tenger-Barna I., Ziol M., de Lédighine V., Douvin C., et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol 2008; 49: 1062–8.

29. Kennedy O. J., Roderick P., Buchanan R., Fallow M., et al. Liver fibrosis and hepatitis C virus infection: a meta-analysis: coffee consumption and the risk of cirrhosis. Aliment Pharmacol Ther 2016; 43: 562–74.

30. Leggio L., Lee M. R. Treatment of alcohol use disorder in patients with alcoholic liver disease. Am J Med 2017; 130: 124–34.

31. Powell W. J., Klatskin G. Duration of survival in patients with Laennec’s cirrhosis. Am J Med 1968; 44: 406–20.

32. Alvarez M. A., Cirera I., Solà R., Bargalló A., Morillas R. M., Planas R. Long-term clinical course of decompensated alcoholic cirrhosis. J Clin Gastroenterol 2011; 45: 906–11.

33. Degré D., Stauber R. E., Englebert G., Sarocchi F., Verset L., Rainer F., et al. Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey’s discriminant function. J Hepatol 2020; 72: 636–42.

34. Lingford-Hughes A., Welch S., Peters L., Nutt D., British Association for Psychopharmacology, Expert Reviewers Group BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful...
use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol 2012; 26: 899–952.

35. Khan A., Tansel A., White D. L., Kayani W. T., Banu S., Lindsay J., et al. Efficacy of psychosocial interventions in inducing and maintaining alcohol abstinence in patients with chronic liver disease: a systematic review. Clin Gastroenterol Hepatol 2016; 14: 191–2020000.

36. Crabb D. W., Im G. Y., Szabo G., Mellinger J. L., Lucey M. R. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2020; 71: 306–33.

37. Day E., Copello A., Hull M. Assessment and management of alcohol use disorders. BMJ 2013; 350: h715.

38. Sinclair J. M. A., Chambers S. E., Shiles C. J., Baldwin D. S. Safety and tolerability of pharmacological treatment of alcohol dependence: comprehensive review of evidence. Drug Saf 2016; 39: 627–45.

39. de Beurrepaire R., Sinclair J. M. A., Heydtmann M., de Beaurepaire R., Sinclair J. M. A., Chambers S. E., Shiles C. J., Baldwin D. S. Safety and maintaining alcohol abstinence in patients with chronic alcohol use disorders. Addiction 2015; 110: 1173–83.

40. Efficacy of baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Front Psychol 2018; 9: 708.

41. Electronic Medicines Compendium (eMC). Adepemd of 50 mg film coated tablets—Summary of Product Characteristics (SmPC) (emc) [internet] [cited 2020 Apr 21]. Available at: https://www.medicines.org.uk/emc/medicine/29642

42. Addolorato G., Leggio L., Ferrulli A., Cardone S., Vonghia L., Mirijello A., et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lanet 2007; 370: 191–22.

43. Hauser P., Fuller B., Ho S. B., Thuras P., Kern S., Dieperink E., et al. The use of baclofen as a treatment for alcohol use disorder: a randomized controlled trial. Addiction 2017; 112: 1173–83.

44. Agabio R., Sinclair J. M., Addolorato G., Aubin H.-J., Beraha E. M., et al. The use of baclofen as a treatment for alcohol use disorder: the Cagliari statement. Lanet Psychiatry 2018; 5: 957–60.

45. Lee B. P., Vittinghoff E., Dodge J. L., Cullaro G., Terrault N. A. National Trends and long-term outcomes of liver transplant for alcohol-associated liver disease in the United States. JAMA Intern Med 2019; 179: 340–8.

46. Barra P., Senzolo M., Adam R., Delvaert V., Karam V., Germani G., et al. Liver transplantation for alcoholic liver disease in Europe: a study from the EUTR (European liver transplant registry). Am J Transplant 2010; 10: 138–48.

47. Calne R. Y., Williams R. Orthotopic liver transplantation: the first 60 patients. BMJ 1977; 1: 471–6.

48. Jepsen P., Lash T. L., VIlstrup H. The clinical course of alcoholic cirrhosis: development of comorbid diseases. A Danish nationwide cohort study. Liver Int 2016; 36: 1696–703.

49. Caly W. R., Strauss E., Currilho F. J., Laudanna A. A. Different degrees of malnutrition and immunological alterations according to the aetiology of cirrhosis: a prospective and sequential study. Nutr J 2003; 2: 10.

50. Günsar E., Raimondo M. L., Jones S., Terreni N., Wong C., Patch D., et al. Nutritional status and prognosis in cirrhotic patients. Aliment Pharmacol Ther 2006; 24: 563–72.

51. Dew M. A., DiMartini A. E., Steel J., Dabb J. D. V., Myaskovsky L., Unruh M., et al. Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs. Liver Transpl 2008; 14: 159–72.

52. Lombardo-Quezada J., Colmenero J., López-Pelayo H., Gavotti C., López A., Crespo C., et al. The high-risk alcoholism relapse score predicts alcohol relapse among liver transplant candidates with less than six months of abstinence. Liver Transpl 2019; 25: It.25460.

53. Pugh R. N. H., Murray-Lyon I. M., Dawson J. L., Pietroni M. C., Williams R. Transsection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646–9.

54. Akinyemiju T., Abara S., Ahmed M., Alam N., Alemayohu M. A., Allen C., et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. JAMA Oncol 2017; 3: 1683–91.

55. Caln R. Y., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646–9.

56. Akinyemiju T., Abara S., Ahmed M., Alam N., Alemayohu M. A., Allen C., et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. JAMA Oncol 2017; 3: 1683–91.

57. Beckett A. G., Livingstone A. V., Hill K. R. Acute alcoholic hepatitis. BMJ 1961; 2: 113–9.

58. Beckett A. G., Livingstone A. V., Hill K. R. Acute alcoholic hepatitis. BMJ 1961; 2: 113–9.

59. Thursz M. R., Richardson P., Allison M., Austin A., Bowers M., Day C. P., et al. Prednisolone or Pentoxifylline for alcoholic hepatitis. N Engl J Med 2015; 372: 1619–28.

60. Moreno C., Deltenre P., Senterre C., Louvet A., Gustot T., Bastens B., et al. Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids. Gastroenterology 2016; 150: 903–1000000000.

61. Cabré E., Rodríguez-Iglesias P., Caballéria J., Quer J. C., Sánchez-Lombraña J. L., Pàris A., et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000; 32: 36–42.

62. Alumirano J., López-Pelayo H., Michelle A., Jones P. D., Ortega L., Gines P., et al. Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: prediction and impact on long-term survival. Hepatology 2017; 66: 1842–53.

63. Singal A. K., Shah V. H. Current trials and novel therapeutic targets for alcoholic hepatitis. J Hepatol 2019; 70: 305–13.

64. Mathurin P., Moreno C., Samuel D., Dumortier J., Salleron J., Durand E., et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365: 1790–800.

65. Im G. Y., Cameron A. M., Lucy M. B. Liver transplantation for alcoholic hepatitis. J Hepatol 2019; 70: 328–34.